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ABSTRACT
Objective: Characterization of magnetic (MRI) features in women undergoing uterine 
fibroid embolization (UFE) and identification of clinical correlates in an African 
population. Materials and Methods: Patients with symptomatic fibroids who are 
selected to undergo UFE at the hospital formed the study population. The baseline 
MRI features, baseline symptom score, short-term imaging outcome, and mid-term 
symptom scores were analyzed for interval changes. Assessment of potential 
associations between short-term imaging features and mid-term symptom scores was 
also done. Results: UFE resulted in statistically significant reduction (P < 0.001) of 
dominant fibroid, uterine volumes, and reduction of symptom severity scores, which 
were 43.7%, 40.1%, and 37.8%, respectively. Also, 59% of respondents had more 
than 10 fibroids. The predominant location of the dominant fibroid was intramural. 
No statistically significant association was found between clinical and radiological 
outcome. Conclusion: The response of uterine fibroids to embolization in the African 
population is not different from the findings reported in other studies from the west. 
The presence of multiple and large fibroids in this study is consistent with the case 
mix described in other studies of African-American populations. Patient counseling 
should emphasize the independence of volume reduction and symptom improvement. 
Though volume changes are of relevance for the radiologist in understanding the 
evolution of the condition and identifying potential technical treatment failures, it 
should not be the main basis of evaluation of treatment success.
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INTRODUCTION
Uterine fibroids, the most common benign tumor of the 
female pelvis, affect 20–50% of women.[1] Hysterectomy 
has been the traditional primary treatment for debilitating 
fibroids. It is estimated that approximately one in three 
women in the United States has undergone hysterectomy 
by the age of 60 years.[2] Uterine fibroids account for 
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approximately 67% of all hysterectomies performed in 
middle‑aged women.[3] The associated health care costs 
and morbidity are not trivial.
Since it was first described in 1995 for the treatment of 
fibroids of the uterus, uterine fibroid embolization (UFE) has 
been shown in numerous studies to be a highly successful 
technique that alleviates fibroid‑related symptoms such 
as heavy menstrual bleeding and bulk‑related symptoms.
Uterine fibroid embolization is performed by selectively 
catheterizing the uterine arteries and embolizing the 
perifibroid plexi with embolic articles. This results in 
ischemic infarction of the fibroids. It is a valuable treatment 
alternative to hysterectomy or myomectomy for many 
women suffering with fibroids.
Uterine fibroids are not only associated with physical 
symptoms, but also affect the quality of life (QOL) in 
the affected women. It was, however, not possible until 
recently to record specific details about the patient’s 
QOL in a uniform and comparable manner due to lack of 
standardized assessment tools. The uterine fibroid symptom 
and QOL questionnaire (UFS‑QOL) presented by Spies and 
colleagues in February 2002 is a practical and validated tool 
for the objective assessment of disease‑specific symptoms, 
their severity, and the impact of fibroids on different aspects 
of the patient’s QOL.[4] The UFS‑QOL allows the comparison 
of a patient’s condition before and after treatment by UFE 
or alternative treatment options.
Though UFE has been used for a long time to treat 
symptomatic uterine fibroids in the developed world, 
it is a relatively new treatment option for fibroids in the 
developing world. No local data, therefore, exist on both 
the clinical and imaging outcome of this treatment option. 
This study was undertaken to characterize the MRI imaging 
features in women undergoing UFE and identify any clinical 
correlates.
Clinical convention holds that symptoms and need for 
treatment are, in large part, related to a combination of 
the type of fibroid, position within the uterus, and fibroid 
size. Fibroids are thus often grouped as one of the following 
four types:
•	 Submucosal (beneath the mucosa, or uterine lining) are 
immediately adjacent to or jut into the uterine cavity
•	 Intramural are entirely within the wall of the uterus
•	 Subserosal (beneath the serosa) distort the contour of 
the outer surface of the uterus; and
•	 Pendunculated are attached to the uterus by a stalk
•	 Transmural fibroids are large fibroids which distort the 
endometrium, occupy a component of the uterine wall, 
distorting the external contour.[5]
The exact etiology of uterine fibroids is not clearly 
understood, but the current working hypothesis is that 
genetic predisposition, prenatal hormone exposure, and 
the effects of hormones, growth factors, and xenoestrogens 
cause fibroid growth. Known risk factors are African 
descent, nulliparity, obesity, polycystic ovary syndrome, 
diabetes, and hypertension.
Several studies have documented an increased incidence 
of uterine fibroids in African women.[6,7] Some evidence 
also indicates that African women are more likely than 
Caucasian women to have larger and more symptomatic 
fibroids at the time of treatment.[8‑13] After accounting 
for body mass index (BMI) and other known risk factors, 
African women experience a higher incidence and relative 
risk of uterine fibroids than other racial and ethnic groups 
including Caucasian, Hispanic, and Asian women.
A few studies have been conducted on this subject in Africa. 
The exact prevalence or incidence of uterine fibroids in the 
continent is not known. A United States Census Bureau and 
Population estimates report extrapolated the prevalence of 
uterine fibroids at 1,649,105 cases (approximately 10‑20% of 
the women population) in Kenya.[14] In a retrospective review 
of 129 surgically managed cases of uterine leiomyoma 
carried out at two large tertiary hospitals in the southwest 
region of Nigeria over a period of 25 years, the commonest 
anatomical positions of the fibroids were multiple positions 
and intramural in 707 (60.9%) and 172 (14.8%) cases, 
respectively. The higher prevalence rate of fibroids in 
African women may be attributable to the gene encoding 
fibroid development or a positive family history of fibroids, 
myometrial irritation following a pelvic infection resulting in 
abnormal uterine growth, or higher levels of estrogen.[13,14]
Imaging plays a critical role in diagnosis and management 
of uterine fibroids. Ultrasonography is usually the initial 
investigation for examining the female pelvis. Ideally, both 
transabdominal (TA) and transvaginal (TV) scans should be 
performed. TV scans are more sensitive for the diagnosis 
of small fibroids; however, when the uterus is bulky or 
retroverted, the uterine fundus may lie outside of the field 
of view. TA views are often of limited value if the patient 
is obese. Ultrasonography is highly operator dependent, 
but in skilled hands, fibroids as small as 5 mm can be 
demonstrated on transvaginal ultrasound.
CT scan is not the investigation of choice for the 
characterization of pelvic masses. Uterine fibroids are often 
seen incidentally on CT scans performed for other reasons.
MRI is the preferred method for accurately characterizing 
pelvic masses. It has been shown to be more sensitive in 
identifying uterine fibroids than ultrasound.[15‑17] It does 
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not involve the use of ionizing radiation and it can readily 
demonstrate the uterine zonal anatomy. Submucosal, 
intramural, and subserosal fibroids are usually easily 
differentiated with MRI and fibroids as small as 5 mm 
in diameter can be demonstrated. Fibroids in relatively 
unusual locations, such as within the cervix, can also be 
identified. MRI is also used to both predict and assess 
the response of fibroids to UFE. On T2‑weighted (T2W) 
images, the normal endometrium shows high signal 
intensity. Surrounding the endometrium is a low‑signal 
band known as the junctional zone, which represents the 
inner myometrium. The remainder of the myometrium is 
of intermediate signal on T2W images.[18] MRI sequences 
should include axial and sagittal T2W images as well as 
T1‑weighted (T1W) images in at least one plane. The routine 
use of gadolinium has been shown not to contribute to 
either fibroid detection or characterization.[19] However, 
gadolinium can be used to determine vascularity when 
assessing the suitability of a fibroid for UFE.
Typically, non‑degenerate fibroids are well‑defined masses of 
low signal intensity as compared to the myometrium on T2W 
images and isointense to the myometrium on T1W images.
In a study conducted in the United States, total 
costs, including hospital care, procedure room, and 
professional fees were estimated for 23 UFE procedures 
and 17 myomectomy procedures. Myomectomy costs 
averaged $7486 per procedure versus $6861 for UFE, 
suggesting a trend toward lower costs for UFE.[20] A total of 
120 UFEs have so far been done at the Aga Khan University 
Hospital, Nairobi by a visiting specialist with over 15 years 
of experience in UFE. The total cost of each procedure is 
approximately 300,000 Kenya shillings (US$ 3530). This is 
considered an extremely expensive procedure by most 
Kenyans. The development of the Nairobi UFE service has 
been described by Dr. Nigel Hacking and colleaques.[21]
The race of the catchment population of the study site is mainly 
African, and therefore, uterine fibroids were presumed to be a 
major health problem. Hysterectomy and myomectomy still 
form the bulk of the treatment options for this disease. UFE 
is a new treatment option in the management of fibroids in 
the local setting. No data, therefore, exists on the radiological 
and clinical response. This study was expected to be useful 
in assessing the response of fibroids to UFE in the local 
population. The data acquired was aimed to help doctors 
to give adequate evidence‑based advice to their patients 
regarding UFE for symptomatic fibroids. This would allow 
the patients to make an informed choice.
Previous studies have correlated imaging and clinical 
response at the same time period post UFE. However, 
literature review reveals that the peak imaging outcome 
is at 3–6 months while the peak clinical outcome is at 
6–24 months. This study, therefore, correlated the peak 
imaging outcome at 3 months post treatment and the peak 
clinical outcome 12 months after treatment.
Specific objectives of this study
• Determine the enhancement pattern of the dominant 
fibroid pre‑ and post‑embolization
• Calculate the baseline volume and the volume change 
of the dominant fibroid and uterus pre‑ and 3–6 months 
post‑embolization
• Enumerate the number of fibroids per patient
• Determine the location of the dominant fibroid
• Identify potential associations between the uterine 
volume (UV), the volume of the dominant fibroid, and 
the symptoms score.
MATERIALS AND METHODS
Methodology
Study site
The study was carried out in the departments of radiology, 
and obstetrics and gynecology at Aga Khan University 
Hospital, Nairobi, an urban tertiary institution. This is a 
264‑bed hospital based in Kenya but receiving patients 
from all over east and central Africa. It has many specialized 
clinics. The Department of Radiology has a 1.5 T General 
Electric (GE) MRI scanner which is operational for 24 h a 
day and 7 days a week.
Data collection
This was both a prospective and retrospective cohort study. 
The data of the baseline MRI scans, baseline symptom scores, 
and the 3‑month follow‑up MRI scans were captured and 
stored in a registry at the radiology and the obstetrics and 
gynecology departments. This represented the retrospective 
aspect of the study. Symptom scores were then acquired 
1 year after UFE during follow‑up at the gynecology clinic 
and this formed the prospective aspect of the study.
Sample population
The sample population consisted of women with 
symptomatic fibroids who chose to undergo UFE and 
met the inclusion criteria which allowed them to have the 
procedure done.
Study population
From the sample population, the study population was 
selected as those with baseline MRI scans, baseline 
symptom score, 3‑month follow‑up MRI scans, and 
12‑month symptoms score.
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Inclusion criteria
• All women undergoing UFE at Aga Khan University 
Hospital, Nairobi who underwent contrast‑enhanced 
pelvic MRI scans (UFE protocol) and filled the baseline 
and follow‑up symptom scores
• Patients who signed an informed consent
Exclusion criteria
• Incomplete MRI studies and symptom score sheets
• Images of poor diagnostic quality
Statistical methods
Sample size calculation
A similar study by Reena et al., reported a mean decrease 
in UV from 588.6 to 393.1 cm3, 3 months after UFE, which 
resulted in a 33.5% change with a standard deviation of 
16.1%.[22] The following formula was, therefore, used to 
determine the required sample size:
2 2
2
4 (Z + Z )
= σ β
σ
n
D
• where n is the required sample size
• σ	is the standard deviation of the mean
• D is the expected size of the confidence interval 
considered here as ± 4, and
• Z and Zα β are the standard normal deviate values 
corresponding to 95% and 90% power, respectively.
Substituting this information in the sample size formula, 
the required sample size is a minimum of 65 patients with 
complete radiological and clinical data.
Data management and analysis
Study data were retrieved from files and records and 
then entered into a spreadsheet (Excel; Microsoft 
Corporation Redmond, Washington USA). Analysis 
was done using the Statistical Program for Social 
Sciences (SPSS) version 17.
Dependent (response) variables
The primary outcome measures were the percentage 
volume reduction of the uterus, dominant fibroid and the 
symptom score changes.
Independent (predictor) variables
The independent variables for the primary analysis were 
the baseline symptom and QOL score, the baseline uterine 
and dominant fibroid volume (DFV).
The independent variables for the secondary analysis were 
uterine and dominant fibroid changes and the symptom 
and QOL scores.
Statistical analysis
The percentage volume reduction of the uterus and 
dominant fibroid was calculated and presented as a mean, 
standard deviation, and range value. The results of the 
symptom score before and after UFE were also calculated 
with the absolute percentage changes given as a mean.
Spearman’s rank correlation coefficient was estimated to 
identify potential associations between changes in the 
symptom severity score, and the percentage UV and DFV 
reduction. Statistical significance was considered to be 
P < 0.05.
Clinical assessment
A self‑administered symptom score filled out by all 
study patients before UFE and at mid‑term follow‑up 
visit, comprised eight questions pertaining to the type 
and severity of symptoms. The eight symptom items 
(questions 1–8) were summarized in a symptom severity 
scale. Response options were presented as five‑level Likert 
scales ranging from “not at all” (1) to “a very great deal” 
(5) in response to “how distressed were you by...?” These 
self‑administered questionnaires for mid‑term symptom 
score were completed by patients during the follow‑up 
visit at the gynecology clinic under the guidance of the 
attending gynecologist or resident. In the unlikely scenario 
that the patient failed to turn up for follow‑up at 1 year, an 
email was sent out to her with an attached questionnaire. 
The email addresses of all the participants were available 
in the registry.
Radiological assessment
Imaging protocol
All the MRI scans were performed using a 1.5 T GM MRI 
scanner. The following protocol was applied:
•	 Three plane localizer
•	 Axial T1 abdomen and pelvis
•	 Axial T1 fat‑saturated pelvis
•	 Axial T2 pelvis
•	 Coronal T2 pelvis
•	 Axial T1 fat‑saturated with contrast pelvis
•	 Sagittal T1 fat‑saturated with contrast pelvis
The MRI images were independently reviewed by two 
consultant radiologists with 5 years of experience post 
residency in the picture archive and communication 
system (PACS) workstation. Any discrepancy was resolved 
by consensus. The baseline and follow‑up volume of the 
uterus and of the dominant fibroid (largest fibroid before 
therapy), the number of fibroids per patient (classified as 
<5, 6–10, and >10), location of the dominant fibroid, and 
enhancement of the dominant fibroid were determined.
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•	 Based on the location of the center of the fibroid, 
dominant fibroids were defined as being subserosal, 
intramural, transmural, or submucosal using a 
modification of the classification of Goodwin et al.[23]
•	 Volumes were determined by measuring the maximum 
extent of the uterus and dominant leiomyoma in three 
planes and multiplying the product by 0.5233 (ellipsoid 
volume formula) as proposed by Orsini et al.[24]
Enhancement pattern of the fibroids was evaluated and 
categorized as strongly enhancing, heterogeneously/
mildly enhancing, or non‑enhancing. The images were 
anonymized for confidentiality using anonymizing software 
in the PACS system (Agfa Impa × 6.4.5.4551).
Ethical considerations
This was a radiological study conducted utilizing the 
images obtained during diagnostic work‑up and follow‑up. 
Images were evaluated and measurements obtained for 
analysis. The study did not influence direct patient care; 
therefore, it was considered that individual consent was 
not appropriate.
The primary investigator sought permission from the 
hospital’s Chief of Staff to access patient files, if needed, 
at the health records department. Any significant finding 
that emerged during image evaluation which had not been 
identified in the original report was communicated to the 
referring physician by way of an addendum to the original 
report. A high level of confidentiality was maintained. The 
reviewers of the imaging data were blind to the patients’ 
biodata and clinical findings. The images were also 
anonymized for extra confidentiality. The study investigator 
had no conflict of interest to declare.
RESULTS
Mean age of the respondents was 41.7 years, with the 
youngest and eldest respondents aged 27 and 49 years, 
respectively [Table 1]. Baseline mean symptoms score, UV, 
and dominant fibroid volume were 24.4, 847.1 cm3, and 
209.2 cm3, respectively [Table 2]. Note that the symptom 
severity score, based on a Likert scale, had a possible 
minimum and maximum of 8 and 40, respectively. The 
percentage reduction in the symptom score, UV, and DFV 
after UFE was 37.8%, 40.1%, and 43.7%, respectively [Table 3]. 
The number of fibroids per participant was categorized into 
three groups: 1–5, 6–10, and > 10. The number of participants 
in each category was then presented as a percentage; 
59% of the participants had more than 10 fibroids each, 
while 21% and 20% of the participants had 1–5 and 6–10 
fibroids each, respectively [Pie Chart 1]. Analysis of the 
enhancement pattern of the dominant fibroids before and 
after UFE revealed that all the dominant fibroids mildly 
or moderately enhanced before UFE and none enhanced 
after UFE [Table 4]. Evaluation of the position of dominant 
fibroids revealed 78% being intramural/transmural, 12% 
being submucosal, and 10% being subserosal [Pie Chart 2]. 
The percentage volume reduction of the dominant fibroid 
and uterus was statistically significant (P < 0.001) [Table 5]. 
However, no statistically significant correlation was found 
between the percentage volume change of both the 
dominant fibroid and uterus and the symptom severity 
score [Table 5].
Table 1: Mean and distribution of the age of the participants
Mean Std. Dev. Min. Max.
Age (years) 41.7 5.2 27 49
Table  2: Baseline symptom scores, baseline volume of the 
dominant fibroid, and baseline volume of uterus of the 
participants
Mean Std. Dev. Min. Max.
Baseline symptom score 24.4 6.6 10 40
Baseline uterine volume (cm3) 847.1 477.7 160 2264
Baseline dominant fibroid 
volume (cm3)
209.2 246.6 0.5 1042
The symptom severity score, based on a 5-point Likert scale, had a possible minimum 
and maximum of 8 and 40, respectively
Table 3: The average percentage reduction of the symptom 
severity scores, volume of the dominant fibroid, and volume 
of the uterus, 3-6 months after UFE
Mean Std. Dev. Min. Max.
Symptom severity score 
% reduction
37.8 21.3 0 80
Uterine volume % reduction 40.1 18.3 5 95
Dominant fibroid % reduction 43.7 25.8 3 99
UFE: Uterine fibroid embolization
Table 4: The enhancement pattern of the dominant fibroids 
before and after UFE
Enhancement pattern Before UFE number (%) After UFE number (%)
Strong 32 (54) 0 (0)
Mild/moderate 27 (46) 8 (14)
None 0 (0) 51 (86)
The absolute number and percentage of fibroids in each pattern of enhancement were 
analyzed. All the dominant fibroids enhanced before UFE and none enhanced after UFE. 
UFE: Uterine fibroid embolization
Table 5: Correlation between dominant fibroid volume, uterine 
volume, and symptom severity score after UFE
Correlation 
coefficient
P value
Percentage volume reduction of the 
dominant fibroid and uterus
0.59 <0.001
Correlation between uterine volume 
reduction and symptom score reduction
−0.08 0.568
Correlation between dominant fibroid volume 
reduction and symptom score reduction
−0.14 0.278
The percentage volume reduction of the dominant fibroid and uterus was statistically 
significant (P<0.001) as shown in the first row. However, no statistically significant 
correlation was found between the percentage volume change of the dominant fibroid 
and uterus and the symptom severity score, as shown in the second and third rows. 
UFE: Uterine fibroid embolization
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Selected images of some of the patients are provided 
[Figures 1–6].
DISCUSSION
UFE is a fairly new treatment option for women with 
uterine fibroids in Kenya and sub‑Saharan Africa at 
large. Data on both clinical and radiological response 
is, therefore, lacking. This study was aimed at assessing 
the response among pioneer African women in a tertiary 
institution in Kenya.
The catchment population of the institution is mainly 
African, who are known to have high prevalence of uterine 
fibroids, and larger and numerous fibroids compared to 
other races.[7‑13] The study was, therefore, structured to 
assess and detect the percentage change in the UV, DFV, 
and symptom score, and their correlation among this 
African population.
Patient selection, UFE, and interpretation of findings 
were carried out by an experienced team comprising an 
interventional radiologist, consultant gynecologist, and 
consultant radiologist. Imaging of the participants was 
carried out in the same facility, using the same scanner and 
standardized imaging protocol. The reviewers were blind 
to clinical information and images were anonymized. All 
these factors helped in reduction of bias during the study.
The high mean UV at baseline corresponding to 847 cm3, 
more than 10 fibroids in 59% of participants, percentage 
change of the dominant fibroid and the uterus being equal 
to 43.7% and 40.1%, respectively, and lack of correlation 
between the clinical and radiological outcome after UFE 180%(52)),%52,'63(53$7,(17WR WR DERYH
Pie Chart 1: The number of fibroids per respondent. The number of fibroids 
per respondent was categorized into three groups: 1–5, 6–10, and >10. The 
number of participants in each category was then presented as a percentage: 
59% of the participants had more than 10 fibroids, 21% had between 6 and 10 
fibroids, while 20% had less than 5 fibroids.
Figure 1: 28-year-old female presenting with menorrhagia and pelvic mass. 
Post-contrast T1-weighted sagittal MRI image before UFE reveals two 
enhancing fibroids (solid arrows).
 /2&$7,212)'20,1$17),%52,' ,0706660
Pie Chart 2: The positions of the dominant fibroids. The intramural (IM) and 
transmural (TM) dominant fibroids were lumped together due to difficulty 
of the reviewers in correctly categorizing the two. Also, 78% of the fibroids 
were intramural/transmural, 12% were submucosal (SM), while 10% were 
subserosal (SS).
Figure 2: 28-year-old female presenting with menorrhagia and pelvic mass. 
Follow-up MRI post UFE, the fibroids demonstrate loss of enhancement 
(arrows), but no significant change in volume.
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were the principal findings in this study. It is therefore clear 
that UFE is a viable option for treating uterine fibroids in 
an African population.
Assessment of the extent of uterine fibroid disease at 
baseline allowed comparison of baseline and follow‑up 
data and evaluation of possible interactions with the clinical 
outcome. MRI showed significant volume reduction of 
both uterus and dominant fibroid at short‑term follow‑up, 
which corresponded to 43.7% and 40.1%, respectively. The 
amount of UV and DFV reduction in this study is in the 
range reported in other studies and case series, mainly 
from the west. In the study by Reena et al., the mean 
decrease in UV was from 588.6 cm3 to 393.1 cm3, which 
resulted in a 33.5% change (P < 001). The reduction in the 
dominant fibroid volume in our study was comparable to 
these studies with a mean volume of 69.4 cm3 before UFE 
and 41.4 cm3 after UAE, which resulted in a 40.1% volume 
reduction (P < 001).[22] Similar observations were also made 
by Andersen et al.,[25] Spies and colleagues,[26] and Walker 
and Pelage,[27] who reported ranges between 35% and 55%.
Severe symptoms and presence of large and numerous 
fibroids among the participants of this study are consistent 
with what have been observed in other studies on African 
and African‑American populations notably by Kjerulff 
et al.[8] Spies and colleagues[26] originally validated their 
symptom score questionnaire in a patient population with 
uterine fibroids in comparison with a healthy control group. 
The baseline symptom severity scores and short‑term 
follow‑up in their patient population correspond to those 
observed in this study. Similar observations have also been 
made in a study by Scheurig et al.
No clear association between baseline UV and DFV, and 
percentage UV and DFV reduction after UFE emerged from 
Figure 3: 33-year-old female presenting with mild pelvic pain and a palpable 
pelvic mass. T1-weighted axial MRI image before UFE shows a single intramural 
fibroid with heterogeneous (mild/moderate) enhancement pattern.
Figure 4: 36-year-old female presenting with pelvic mass, lower abdominal 
pain, infertility, and menorrhagia. T1-weighted sagittal MRI image before UFE 
reveals a large enhancing fibroid (thick arrow) and a small non-enhancing 
fibroid (thin arrow). 
Figure 5: 36-year-old female presenting with pelvic mass, lower abdominal 
pain, infertility, and menorrhagia. Follow-up MRI post UFE shows  the fibroids 
has completely regressed (arrow).
Figure 6: 34 year old female presenting with heavy menses. T1-weighted 
sagittal post-contrast MRI image before UFE shows bulky uterus with multiple 
fibroids (arrows).
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the results of previously reported large case series.[26,28] 
Likewise, in this study, no association was found between 
the number of fibroids, the localization of the dominant 
leiomyoma at baseline MRI, and the UV/DFV reduction 
after UFE. In addition, no significant correlation between 
improvement in symptoms and imaging findings was 
identified. However, strong enhancement at baseline 
correlated to a better outcome.
In the study by Reena et al., it was observed that clinical 
and imaging response to UFE was lower in older patients 
and those with larger fibroids/UV at presentation. Our 
study was not powered to detect these differences. Future 
studies may, therefore, look into these parameters. A study 
in South Africa aimed at assessing the effect of large uterus 
on the outcome of UFE did not, however, reveal significant 
differences between those with UVs below and above 
780 cm3. This is likely related to embolic particle distribution 
per unit volume of the fibroid. This may also explain why 
the response to UFE in our study is similar to that in the 
west, even though our participants had, on average, large 
and numerous fibroids. Other factors such as diet and 
living conditions, which were not assessed in this study, 
could also play a role. Future studies may, therefore, take 
into consideration the number of embolic particles per 
fibroid volume, environmental factors, and lifestyle of the 
participants.
Significant reduction in the uterine and dominant fibroid 
after UFE is due to sluggish or no blood flow in the uterine 
arteries, which are the vessels that typically supply large 
feeding branches to the fibroids. The enhancement of 
fibroids is related to blood flow. Fibroids with good blood 
flow, therefore, enhance strongly and vice versa. This 
explains why fibroids which were strongly enhancing 
at baseline had better response after UFE. Moderately 
or mildly enhancing fibroids had lesser response due to 
the fact that part of the fibroids had already undergone 
degeneration at the time of embolization. Patient selection 
is, therefore, important for successful UFE.
Lack of statistically significant correlation between 
volume change of the uterus and dominant fibroid and 
the symptom scores in our study has implications on the 
clinicians and policy makers. The follow‑up MRI scans done 
in many centers might not be warranted unless for specific 
reasons like assessment of patients with complications. This 
will likely reduce the cost of undergoing UFE and make it 
more accessible in the developing world.
Limitations of the study
A few limitations were encountered in the study. 
The first is that follow‑up MRI was not uniformly 
performed at the intended 3 months post UFE. Some 
participants (approximately 10%) were scanned up to 
6 months post UFE. The second limitation is that this was 
a post graduate dissertation study, and therefore, funds 
were limited. A small sample size was, therefore, chosen 
and studied to only detect changes in the uterine and 
dominant fibroid volumes and symptoms scores. Many 
other parameters such as dietary and environmental factors 
influencing response to treatment were not assessed. 
Long‑term changes (more than 1 year) were also not 
studied.
CONCLUSION
The response of uterine fibroids to embolization in the 
African population is not different from the findings 
reported in other studies from the west. The presence of 
multiple and large fibroids in this study is consistent with 
the case mix described in the studies of African‑American 
populations.
Patient counseling should emphasize the independence 
of volume reduction and symptom improvement. Volume 
changes are of relevance for the radiologist in aiding 
understanding of the evolution of the condition and 
identifying potential technical treatment failures, but should 
not be the main basis of evaluation of treatment success.
ACKNOWLEDGMENTS
The authors wish to thank the management, staff, faculty 
members, and residents of Aga Khan University Hospital for their 
invaluable input and for being a great source of support during 
the study. Appreciation also goes to the radiology department 
secretary who assisted in the proofreading and editing of this 
paper and to the departmental IT specialist who assisted with 
formatting and other technical aspects.
REFERENCES
1. VerKauf BS. Changing trends in treatment of leiomyomata uteri. Curr 
Opin Obstet Gynecol 1993;5:301‑10.
2. Pokras R, Hufnagel VG. Hysterectomy in the United States, 1965‑84. 
Am J Public Health 1988;78:852‑3.
3. Chryssikopoulos  A, Loghis  C. Indications and results of total 
hysterectomy. Int Surg 1986;71:188‑94.
4. Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz‑Murphy K, 
Gonzalves SM. The UFS‑QOL, a new disease‑specific symptom and 
health‑related quality of life questionnaire for leiomyomata. Obstet 
Gynecol 2002;99:290‑300.
5. Wallach EE, Vlahos NF. Uterine myomas: An overview of development, 
clinical features, and management. Obstet Gynecol 2004;104:393‑406.
6. Chalas  E, Constantino  JP, Wickerham  DL, Wolmark  N, Lewis  GC, 
Bergman C, et al. Benign gynaecologic conditions among participants 
in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 
2005;192:1230‑9.
7. Wise LA, Palmer JR, Stewart EA, Rosenberg L. Age‑specific incidence 
Mutai, et al.: Radiological and clinical outcome after uterine fibroid embolization
9 Journal of Clinical Imaging Science | Vol. 5 | Issue 1 | Jan-Mar 2015 
rates for self‑reported uterine leiomyomata in the Black Women’s Health 
Study. Obstet Gynecol 2005;105:563‑8.
8. Kjerulff  KH, Langenberg  P, Seidman  JD, Stolley  PD, Guzinski  GM. 
Uterine leiomyomas. Racial differences in severity, symptoms and age 
of diagnosis. J Reprod Med 1996;41:483‑90.
9. Ross  RK, Pike  MC, Vessey  MP, Bull  D, Yeates  D, Casagrande  JT. 
Risk factors for uterine fibroids: Reduced risk associated with oral 
contraceptives. Br Med J (Clin Res Ed) 1986;293:359‑62.
10. Ligon  AH, Morton  CC. Leiomyomata: Heritability and cytogenetic 
studies. Hum Reprod Update 2001;7:8‑14.
11. Chiaffarino  F, Parazzini  F, La Vecchia  C, Marsico  S, Surace  M, 
Ricci E. Use of oral contraceptives and uterine fibroids: Results from a 
case‑control study. Br J Obstet Gynaecol 1999;106:857‑60.
12. Lumbiganon  P, Rugpao  S, Phandhu‑fung S, Laopaiboon  M, 
Vudhikamraksa  N,  Werawatakul   Y.  Protect ive ef fect  of 
depot‑medroxyprogesteroneacetate on surgically treated uterine 
leiomyomas: A multicenter case‑control study. Br J Obstet Gynaecol 
1996;103:909‑14.
13. Baird  DD, Dunson  DB, Hill  MC, Cousins  D, Schectman  JM. High 
cumulative incidence of uterine leiomyoma in black and white women: 
Ultrasound evidence. Am J Obstet Gynecol 2003;188:100‑7.
14. Statistics by Country for Uterine Fibroids. Available from: http://
www.rightdiagnosis.com/u/uterine_fibroids/stats‑country.htm. 
[Last accessed on 2012 Aug 20].
15. Dudiak  CM, Turner  DA, Patel  SK, Archie  JT, Silver  B, Norusis  M. 
Uterine leiomyomas in the infertile patient: Preoperative localization 
with MR imaging versus US and hysterosalpingography. Radiology 
1988;167:627‑30.
16. Zawin  M, McCarthy  S, Scoutt  LM, Comite  F. High‑field MRI and 
US evaluation of the pelvis in women with leiomyomas. Magn Reson 
Imaging 1990;8:371‑6.
17. Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen F. Accuracy 
of magnetic resonance imaging and transvaginal ultrasonography in 
the diagnosis, mapping, and measurement of uterine myomas. Am J 
Obstet Gynecol 2002;186:409‑15.
18. Vitiello D, McCarthy S. Diagnostic imaging of myomas. Obstet Gynecol 
Clin North Am 2006;33:85‑95.
19. Hricak H, Finck S, Honda G, Göranson H. MR imaging in the evaluation 
of benign uterine masses: Value of gadopentate dimeglumine‑enhanced 
T1‑weighted images. AJR Am J Roentgenol 1992;158:1043‑50.
20. Shnitzler D, Oehler E. Uterine Fibroid Embolization, a Minimally 
Invasive Treatment for Uterine Fibroids. Fact sheet. Society of 
Interventional Radiology. [Downloaded from www.drrws.com on 27th 
July 2012].
21. Hacking N. Costing Issues and UAE in the Developing World. 
In:  Reidy J, et al. editors. Radiological Interventions in Obstetrics 
and Gynaecology, Medical Radiology. Diagnostic Imaging, DOI: 
10.1007/174_2014_1011, Springer Berlin Heidelberg 2014.
22. Jha RC, Ascher SM, Imaoka I, Spies JB. Symptomatic Fibroleiomyomata: 
MR Imaging of the uterus before and after uterine arterial embolization. 
Radiol 2000;217:228‑35.
23. Goodwin SC, Bonilla SM, Sacks D, Reed RA, Spies JB, Landow WJ, et al.; 
Members of the Reporting Standards for Uterine Artery Embolization 
(UAE) Subcommittee, the Members of the UAE Task Force Standards 
Subcommittee, and the Members of the SCVIR Technology Assessment 
Committee. Reporting standards for uterine artery embolization for the 
treatment of uterine leiomyomata. J Vasc Interv Radiol 2001;12:1011‑20.
24. Orsini LF, Salardi S, Pilu G, Bovicelli L, Cacciari E. Pelvic organs in 
premenarcheal girls: Real‑time ultrasonography. Radiol 1994;153:113‑6.
25. Andersen PE, Lund N, Justesen P, Munk T, Elle B, Floridon C. Uterine 
artery embolization of symptomatic uterine fibroids. Initial success and 
short‑term results. Acta Radiologica 2001;42:234‑38.
26. Spies JB, Roth AR, Jha RC, Gomez‑Jorge J, Levy EB, Chang TC, 
et al. Leiomyomata treated with uterine artery embolization: Factors 
associated with successful symptom and imaging outcome. Radiol 
2002;222:45‑52.
27. Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic 
fibroids: Clinical results in 400 women with imaging follow up. Br J 
Obstet Gynaecol 2002;109:1262‑72.
28. Pron G, Bennett J, Common A, Wall J, Asch M, Sniderman K; Ontario 
Uterine Fibroid Embolization Collaboration Group. The Ontario 
Uterine Fibroid Embolization Trial. Part 1. Uterine fibroid reduction 
and symptom relief after uterine artery embolization for fibroids. Fertil 
Steril 2001;75:115‑32.
Source of Support: The study was funded by the Aga Khan 
University, Conflict of Interest: None declared.
